{"id":"NCT02195687","sponsor":"Allergan","briefTitle":"BOTOX® in the Treatment of Crow's Feet Lines in China","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09","primaryCompletion":"2015-02","completion":"2015-06","firstPosted":"2014-07-21","resultsPosted":"2016-03-14","lastUpdate":"2016-03-14"},"enrollment":417,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Lateral Canthal Lines","Crow's Feet Lines"],"interventions":[{"type":"BIOLOGICAL","name":"botulinum toxin Type A","otherNames":["BOTOX®"]},{"type":"DRUG","name":"Normal Saline","otherNames":[]}],"arms":[{"label":"botulinum toxin type A","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared with placebo in patients with moderate to severe crow's feet lines (lateral canthal lines).","primaryOutcome":{"measure":"Percentage of Subjects Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale-Asian (FWS-A)","timeFrame":"Day 30","effectByArm":[{"arm":"Botulinum Toxin Type A","deltaMin":63.9,"sd":null},{"arm":"Placebo","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":6},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":["34976286"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":316},"commonTop":[]}}